However, due to increased data regarding its safety and proven long-term efficacy, TNF-α inhibitors are favored over IL-17 inhibitors; according to the update offered by the American College of Rheumatology/Spondylitis Association in 2019, TNF inhibitors are recommended over IL-17 inhibitors as the first biologic treatment to be used [44]. The gene discussed is IL17A; the disease is spondylitis.